Beta Blockers in Acute NSTEMI Management
Indications and Timing
- The American College of Cardiology recommends beta blockers as a Class I indication for all NSTEMI patients without contraindications, with treatment beginning within the first 24 hours of presentation 4, 5
- The American Heart Association suggests oral administration as the preferred initial route for most patients, though IV beta blockers may be considered in specific situations such as hypertension 6, 7
Contraindications and Caution Scenarios
- The American College of Cardiology advises against administering beta blockers to patients with signs of heart failure 1, 8
- The American Heart Association recommends caution in patients with evidence of low-output state 7, 3
- The American College of Cardiology suggests that beta blockers should not be administered to patients with increased risk for cardiogenic shock (age >70 years, systolic BP <120 mmHg, heart rate >110 or <60 bpm, increased time since symptom onset) 2
- The American Heart Association advises against beta blocker administration in patients with PR interval >0.24 seconds or second/third-degree heart block 7, 8
- The American College of Cardiology recommends caution in patients with active asthma or reactive airway disease 1, 7
Benefits in NSTEMI
- Continued beta blocker administration post-NSTEMI is recommended for secondary prevention, as suggested by the American Heart Association 6, 4
Alternative Approaches
- The American College of Cardiology recommends non-dihydropyridine calcium channel blockers (verapamil or diltiazem) as initial therapy when beta blockers are contraindicated, in the absence of severe LV dysfunction 1, 2
- The American Heart Association suggests that extended-release forms of non-dihydropyridine calcium channel blockers may be considered instead of beta blockers in some patients (Class IIb recommendation) 7, 9